Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells

Joint Bone Spine

Volumn 80, Issue 2, 2013, Pages 195-200

  Lazzerini, Pietro Enea ^a   Capperucci, Caterina ^a   Spreafico, Adriano ^a   Capecchi, Pier Leopoldo ^a   Niccolini, Silvia ^a   Ferrata, Paolo ^a   Frediani, Bruno ^a   Galeazzi, Mauro ^a   Laghi Pasini, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Human osteoblasts; Il 6; Inflammation; Osteoporosis; Rosuvastatin

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOPRENOID; MESSENGER RNA; MEVALONIC ACID; OSTEOPROTEGERIN; ROSUVASTATIN;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; OSTEOBLAST; POLYMERASE CHAIN REACTION; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN PRENYLATION;

AGED; BONE RESORPTION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA; DITERPENES; FARNESOL; FEMUR HEAD; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MEVALONIC ACID; MIDDLE AGED; OSTEOBLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; PYRIMIDINES; RNA, MESSENGER; SULFONAMIDES; TERPENES;

EID: 84875520629     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.07.007     Document Type: Article

References (40)

1. Zhou Q., Liao J.K. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 2010, 74:818-826.
2. Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84:413-428.
3. Tang Q.O., Tran G.T., Gamie Z., et al. Statins: under investigation for increasing bone mineral density and augmenting fracture healing. Expert Opin Investig Drugs 2008, 17:1435-1463.
4. Lazzerini P.E., Capecchi P.L., Selvi E., et al. Statins and the joint: multiple targets for a global protection?. Semin Arthritis Rheum 2011, 40:430-446.
5. Manolagas S.C., Jilka R.L. Bone marrow, cytokines, and bone remodelling. emerging insights into the pathophysiology of osteoporosis. N Eng J Med 1995, 332:305-311.
6. Braun T., Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep 2012, 10:101-108.
7. Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol 2010, 25:399-405.
8. Ghittoni R., Patrussi L., Pirozzi K., et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 2005, 19:605-607.
9. Ghittoni R., Lazzerini P.E., Laghi-Pasini F., et al. T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives. Inflamm Allergy Drug Targets 2007, 6:3-16.
10. Kothe H., Dalhoff K., Rupp J., et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000, 101:1760-1763.
11. Lazzerini P.E., Lorenzini S., Selvi E., et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 2007, 25:696-700.
12. Dombrecht E.J., Van Offel J.F., Bridts C.H., et al. Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes. Clin Exp Rheumatol 2007, 25:534-539.
13. Kim Y.S., Ahn Y., Hong M.H., et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J Cardiovasc Pharmacol 2007, 49:376-383.
14. Awad A.S., El Sharif A. Immunomodulatory effects of rosuvastatin on hepatic ischemia/reperfusion induced injury. Immunopharmacol Immunotoxicol 2010, 32:555-561.
15. Semenova A.E., Sergienko I.V., Masenko V.P., et al. The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients. Acta Cardiol 2009, 64:405-409.
16. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target?. Can J Cardiol 2010, 26:41A-44A.
17. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
18. Frediani B., Spreafico A., Capperucci C., et al. Long-term effects of neridronate on human osteoblastic cell cultures. Bone 2004, 35:859-869.
19. Ramakers C., Ruijter J.M., Lekanne Deprez R.H., et al. Assumption-free analysis of quantitative Real-Time polymerase chain reaction (PCR) data. Neurosci Lett 2003, 339:62-66.
20. Hellemans J., Mortier G., De Paepe A., et al. qBase relative quantification framework and software for comment management and automated analysis of real-time quantitative PCR data. Genome Biol 2007, 8:R19.
21. Sims N.A., Walsh N.C. GP130 cytokines and bone remodelling in health and disease. BMP Rep 2010, 43:513-523.
22. Kwan Tat S., Padrines M., Théoleyre S., et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004, 15:49-60.
23. Le Goff B., Blanchard F., Berthelot J.M., et al. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 2010, 77:201-205.
24. Ghishan F.K., Kiela P.R. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2011, 300:G191-G201.
25. Singh T., Newman A.B. Inflammatory markers in population studies of aging. Ageing Res Rev 2011, 10:319-329.
26. Woo J.T., Yonezawa T., Cha B.Y., et al. Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation, function, and survival. J Pharmacol Sci 2008, 106:547-554.
27. Kaji H., Kanatani M., Sugimoto T., et al. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res 2005, 37:589-592.
28. Hughes A., Rogers M.J., Idris A.I., et al. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int 2007, 81:403-413.
29. Monjo M., Rubert M., Ellingsen J.E., et al. Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells. Cell Physiol Biochem 2010, 26:647-656.
30. Kanazawa I., Yamaguchi T., Yamauchi M., et al. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia. Intern Med 2009, 48:1869-1873.
31. Ertugrul D.T., Yavuz B., Cil H., et al. STATIN-D Study. Comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther 2010, 10.1111/j.1755-5922.2010.00141.x.
32. Devlin R.D., Reddy S.V., Savino R., et al. IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res 1998, 13:393-399.
33. Ayukawa Y., Yasukawa E., Moriyama Y., et al. Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 107:336-342.
34. Sondergaard T.E., Pedersen P.T., Andersen T.L., et al. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol 2009, 27:17-22.
35. Viereck V., Grundker C., Blaschke S., et al. Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem 2005, 96:1244-1253.
36. Ben-Tal Choen E., Hohensinner P.J., Kaun C., et al. Statins decrease TNF-α-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol 2007, 73:77-83.
37. Nellemann B., Gormsen L.C., Dollerup J., et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care 2007, 30:3122-3124.
38. Kadoglu N.P., Gerasimidis T., Moumtzouoglou A., et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg 2008, 34:661-668.
39. Lambert C., Oury C., Dejardin E., et al. Further insights in the mechanisms of interleukin-1β stimulation of osteoprotegerin in osteoblast-like cells. J Bone Miner Res 2007, 22:1350-1361.
40. Barter M.J., Hui W., Lakey R.L., et al. Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation. Ann Rheum Dis 2010, 69:2189-2198.